✦ LIBER ✦

Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

✍ Scribed by Shinya Fujisawa; Ryuzo Ohno; Kazuyuki Shigeno; Naohi Sahara; Satoki Nakamura; Kensuke Naito; Miki Kobayashi; Kaori Shinjo; Akihiro Takeshita; Yoshinari Suzuki; Hisakuni Hashimoto; Kenji Kinoshita; Masahito Shimoya; Toshikazu Kaise; Kazunori Ohnishi

Publisher: Springer
Year: 2006
Tongue: English
Weight: 225 KB
Volume: 59
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-006-0288-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Successful treatment with arsenic trioxi

Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia

✍ H. Agis; A. Weltermann; G. Mitterbauer; R. Thalhammer; M. Edelhäuser; H. L. Seew 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 223 KB

Arsenic in the cerebrospinal fluid of a

Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement

✍ Sabine Knipp; Norbert Gattermann; Marc Schapira; Herbert Käferstein; Ulrich Germ 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 92 KB

Successful Unrelated Bone Marrow Transpl

✍ Michiaki Mikoshiba; Kazuteru Ohashi; Naoko Takei; Yoshiki Okuyama; Yasuharu Maed 📂 Article 📅 2002 🏛 Carden Jennings Publishing 🌐 English ⚖ 76 KB

Entry of elemental arsenic into the cent

Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment

✍ Wing-Yan Au; Sidney Tam; Yok-Lam Kwong 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 70 KB

Arsenic trioxide and low-dose cytarabine

Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia

✍ Gail J. Roboz; Ellen K. Ritchie; Tania Curcio; Juliette Provenzano; Rebecca Carl 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

## Abstract ## BACKGROUND. Acute myeloid leukemia (AML) carries a dismal prognosis in older patients. In this study, the authors evaluated the safety and efficacy of arsenic trioxide combined with low‐dose cytarabine in untreated patients aged ≥60 years with AML. ## METHODS. In a phase 1/2 desig

Clinical efficacy of arsenic trioxide in

Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement

✍ Patrizia Zappasodi; Marianna Rossi; Ilaria Ambaglio; Paolo Bernasconi; Alessandr 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 146 KB